prediction tool. This 2-dimensional sequence was translated into a 3-dimensional structure using Acerlys Discovery Studio (ADS). Core 1 and 2 sugars were generated using Ambertools glycol tool protocols, 2 saved as pdb files and incorporated into the appropriate amino acid using the small ligand and mutate tools which are built into ADS. These sugars were incorporated into amino acids predicted to be glycosylated using the Hamby and Hirst's glycosylation prediction tool, 1 and at levels of mucin glycosylation observed in the CF lung.
3
The Alpha-L-Guluronate structure was downloaded in the form of the crystal structure, PDB ID 1J1N 4 and converted into a repeating unit using ADS. This repeating unit was elongated to make the OligoG structure file. MUC5AC and OligoG structures were then amalgamated into a single pdb file for simulation.
Partial charges for the sugars and OligoG molecules were calculated using Ambertools and the Amber99 force field as were atom types (Supporting Information Tables 2-6 Mean IR spectra were generated and a second derivative spectra was performed using OPUS and the R Statistical Programming Environment (www.R-project.org).
Pre-clinical studies with OligoG CF-5/20 in experimental animals. Initial studies with tritium-labelled OligoG CF-5/20 (Supporting Information Table 9 ) showed no toxicity, and rapid excretion in faeces and urine (after oral or IV administration respectively). Following this, inhalation studies with aerosolized OligoG CF-5/20 were performed in Sprague-Dawley rats using a modular, flow-past system. Aerosols of 6% (w/v) OligoG CF-5/20 in sterile water were generated using HEART ® airjet nebulizers (Westmed, Tuscon, Arizona, USA). In the first series of experiments (Supporting Information Table 10 ), rats were assigned to 6% OligoG CF-5/20 dose for variable exposure times and screened for changes in body-weight, food consumption, and respiratory function. In the second series of experiments (Supporting Information Table 11 ), daily inhalational dosing was performed with a 14 day off-test recovery period to assess the reversibility of any observed effects. Rats were screened for clinical, biochemical and pathological changes (Supporting Information Table 12 ).
Since the final drug formulation was to be a DPI (Dry Powder for Inhalation) a bridging study was required to ensure comparability with the previously used nebulized formulation.
The DPI formulation of OligoG CF-5/20 was developed with the purpose of improving patient compliance and enabling increased doses to be administered. The product is manufactured in compliance with Good Manufacturing Practice as a spray dried powder with a particle size distribution for inhalation D10 ≤2.5 µm, D50 ≤5 µm, D90 ≤10 µm. Healthy male subjects (28 in total) aged 18 to 65 years were assigned randomly to an intervention group (single-or multiple-dose) or control group (Supporting Information Table   13 ). Randomization was computer-generated and testing done by aerosol delivery system Sequential anterior and posterior images of the thorax/abdomen and lateral images of the head/neck were acquired. Images of the device hardware were acquired pre-and postdose, using a Siemens E-Cam gamma camera with a 53.3 cm field of view and fitted with a low energy high-resolution collimator. Image analysis was performed using the WebLink software. Lung and extra-pulmonary deposition of radiolabel, including retention in the equipment, were characterized and assessed using paired t-tests (Supporting Information   Table 13 ).
Rheological analysis of cystic fibrosis sputum. Samples of CF sputum (n=3) were divided and treated with 10% (v/v) distilled water (control) or 2% OligoG (incubated at 37°C for 4 h) to assess the extensional thinning behavior. A capillary break-up extensional rheometer was employed using two aligned 7 mm plates. Live recording was taken of a "stepstrain" and the specimen fell at a time-lag. The extensional rheometer was manufactured 'in house' and the recording device was a FASTCAM ultima APX I2 (Photon Europe Ltd).
Further experiments were conducted employing shear rheology. Each sputum sample (n=23; from 7 patients) was divided into a control and 2% OligoG CF-5/20 treated experiment (Supporting Information Fig. 3a ; see patient details in Supporting Information Table 13 ). 
